CALCIUM PHOSPHATE BONE REPAIR MATERIALS

磷酸钙骨修复材料

• 批准号: 7078524
• 负责人: LAURENCE C. CHOW
• 金额: $ 27.83万
• 依托单位: AMERICAN DENTAL ASSOCIATION FOUNDATION
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-05-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7078524
• 关键词: acidity /alkalinity; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; biomechanics; biotechnology; calcium phosphate; chitin; composite resins; dental bonding material; dogs; elastomers; electron probe spectrometry; endosseous dental implant; hardness; histopathology; hydroxyapatites; mandible /maxilla; oral facial restoration material; physiologic bone resorption; solubility; statistics /biometry; tensile strength

DESCRIPTION (provided by applicant): The first self-hardening calcium phosphate cements (CPCs) were developed in our laboratory under the present and a previous N1H grant. One such CPC material has been in clinical use since 1996 for repairing cranial defects in humans. In recent years, several additional CPCs have been approved by the FDA, but due to limitations in both physical and in vivo properties, their uses remain largely confined to craniofacial and selected non-load bearing orthopedic applications. Through the following Aims, the objective of the present proposal is to determine how to build into CPC materials those attributes that are of critical importance for different applications so that CPC materials can be useful for a wider range of clinical applications. Aim 1. To develop and study the properties of CPCs that form products comprising a wide range of phase compositions and resorption rates suitable for different clinical applications. Aim 2. To develop and study the properties of elastomeric CPC materials that would provide compliance for micro-motions within the tissues and resist fracturing. Materials with these properties should be useful for applications such as periodontal defect repair, ridge augmentation, and spinal fusion. Aim 3. To develop and study the properties of rapid setting moldable/injectable premixed CPCs that are stable in the package and harden at tissue defect site. These CPCs can be more easily delivered to the defect site and possibly with reduced surgical invasions. Aim 4. To evaluate in vivo properties of selected CPC materials developed in the first three Aims in animal models. The following three animal studies will be conducted: (1) Evaluation of in vivo resorption rates of new CPC materials developed in Aim 1 that exhibit a wide range of in vitro acid dissolution rates. The study will employ a dog model, and histopathological measurements and electron microprobe analyses will be used to obtain quantitative data on in vivo resorption/bone replacement rates. (2) Evaluation of in vivo characteristics of non-rigid CPCs developed in Aim 2. The study, employing a dog model, will focus on the biocompatibility and resorption and bone replacement of CPC-chitosan composites in which the CPC and chitosan components have closely matched in vitro acid dissolution rates. (3) Evaluation of premixed, injectable CPC in a dog model to determine biocompatibility and osteoconductivity of these materials, which contain non-calcium phosphate components that have not been evaluated in vivo in previous studies.

描述（由申请人提供）：第一批自硬化磷酸钙水泥（CPCs）是在本实验室和之前的N1H资助下开发的。自1996年以来，一种这样的CPC材料已用于临床，用于修复人类的颅骨缺陷。近年来，FDA批准了几种额外的CPCs，但由于物理和体内特性的限制，它们的使用主要局限于颅面和选择的非承重骨科应用。通过以下目标，本提案的目标是确定如何将对不同应用至关重要的属性构建到CPC材料中，以便CPC材料可以用于更广泛的临床应用。